BEAM vs. RXRX

Last updated Apr 2, 2026

Compare and contrast key facts about Beam Therapeutics Inc. (BEAM) and Recursion Pharmaceuticals, Inc. (RXRX).

Performance

BEAM vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Beam Therapeutics Inc. (BEAM) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

BEAM vs. RXRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
BEAM Beam Therapeutics Inc.	-12.63%	11.77%	-8.89%	-30.40%	-50.92%	9.63%
RXRX Recursion Pharmaceuticals, Inc.	-25.18%	-39.50%	-31.44%	27.89%	-54.99%	-45.27%

Fundamentals

Market Cap BEAM : $2.54B RXRX : $1.61B
EPS BEAM : -$0.78 RXRX : -$1.39
PS Ratio BEAM : 97.47 RXRX : 19.03
PB Ratio BEAM : 2.05 RXRX : 1.43
Total Revenue (TTM) BEAM : $25.63M RXRX : $74.56M
Gross Profit (TTM) BEAM : -$284.71M RXRX : $3.73M
EBITDA (TTM) BEAM : -$352.98M RXRX : -$579.69M

Returns By Period

In the year-to-date period, BEAM achieves a -12.63% return, which is significantly higher than RXRX's -25.18% return.

BEAM

• 1D: 1.64%
• 1M: -15.58%
• YTD: -12.63%
• 6M: 0.37%
• 1Y: 37.34%
• 3Y*: -7.52%
• 5Y*: -21.20%
• 10Y*: —

RXRX

• 1D: -0.33%
• 1M: -15.70%
• YTD: -25.18%
• 6M: -40.00%
• 1Y: -39.94%
• 3Y*: -22.87%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BEAM vs. RXRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BEAM

BEAM Risk / Return Rank: 58
BEAM Sharpe Ratio Rank: 58
BEAM Sortino Ratio Rank: 62
BEAM Omega Ratio Rank: 58
BEAM Calmar Ratio Rank: 56
BEAM Martin Ratio Rank: 55

RXRX

RXRX Risk / Return Rank: 18
RXRX Sharpe Ratio Rank: 19
RXRX Sortino Ratio Rank: 22
RXRX Omega Ratio Rank: 23
RXRX Calmar Ratio Rank: 15
RXRX Martin Ratio Rank: 11

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BEAM vs. RXRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Beam Therapeutics Inc. (BEAM) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BEAM	RXRX	Difference
Sharpe ratio Return per unit of total volatility	0.49	-0.48	+0.97
Sortino ratio Return per unit of downside risk	1.30	-0.32	+1.62
Omega ratio Gain probability vs. loss probability	1.15	0.97	+0.19
Calmar ratio Return relative to maximum drawdown	0.63	-0.72	+1.35
Martin ratio Return relative to average drawdown	1.39	-1.43	+2.82
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BEAM vs. RXRX - Sharpe Ratio Comparison

The current BEAM Sharpe Ratio is 0.49, which is higher than the RXRX Sharpe Ratio of -0.48. The chart below compares the historical Sharpe Ratios of BEAM and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	BEAM	RXRX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.49	-0.48	+0.97
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.28	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.05	-0.40	+0.45

Correlation

The correlation between BEAM and RXRX is 0.62, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

BEAM vs. RXRX - Dividend Comparison

Neither BEAM nor RXRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

BEAM vs. RXRX - Drawdown Comparison

The maximum BEAM drawdown since its inception was -89.12%, roughly equal to the maximum RXRX drawdown of -93.13%. Use the drawdown chart below to compare losses from any high point for BEAM and RXRX.

Drawdown Indicators

	BEAM	RXRX	Difference
Max Drawdown Largest peak-to-trough decline	-89.12%	-93.13%	+4.01%
Max Drawdown (1Y) Largest decline over 1 year	-38.15%	-58.17%	+20.02%
Max Drawdown (5Y) Largest decline over 5 years	-89.12%	—	—
Current Drawdown Current decline from peak	-81.87%	-92.60%	+10.73%
Average Drawdown Average peak-to-trough decline	-59.31%	-74.78%	+15.47%
Ulcer Index Depth and duration of drawdowns from previous peaks	17.25%	29.48%	-12.23%

Volatility

BEAM vs. RXRX - Volatility Comparison

Beam Therapeutics Inc. (BEAM) has a higher volatility of 17.48% compared to Recursion Pharmaceuticals, Inc. (RXRX) at 14.66%. This indicates that BEAM's price experiences larger fluctuations and is considered to be riskier than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BEAM	RXRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.48%	14.66%	+2.82%
Volatility (6M) Calculated over the trailing 6-month period	53.97%	54.53%	-0.56%
Volatility (1Y) Calculated over the trailing 1-year period	77.28%	83.97%	-6.69%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	75.45%	94.52%	-19.07%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	80.54%	94.52%	-13.98%

Financials